Associated Papers
Calcitonin Thresholds for Prediction of Medullary Thyroid Carcinoma and its Clinical Response in MEN2A Gene Carriers.
Prete A et al.
The Journal of Clinical Endocrinology and Metabolism, 2026
RET Gene Alterations in Clinical Practice: A Comprehensive Review and Database Update.
Ricciardi Tenore C et al.
Genes, 2025
Geospatial inheritance across the breath of the RET mutational landscape of multiple endocrine neoplasia 2A.
Machens A et al.
Endocrine, 2025
Approach to the Patient: Hereditary Medullary Thyroid Carcinoma.
Shariq OA et al.
The Journal of Clinical Endocrinology and Metabolism, 2025
The Genomic Landscape of Romanian Non-Small Cell Lung Cancer Patients: The Insights from Routine NGS Testing with the Oncomine Dx Target Panel at the PATHOS Molecular Pathology Laboratory.
Gaal OI et al.
Cancers, 2025
Circulating tumor DNA profiling for non-invasive genomic analysis in Indian lung cancer patients: A real-world experience.
Jha P et al.
The Journal of Liquid Biopsy, 2025
RET (C620R) Mutation in a Hirschsprung Disease Family: A Case Report Unveiling Asymptomatic Pheochromocytoma and Unmanifested Medullary Thyroid Carcinoma.
Tanaka Y et al.
Cureus, 2025
RET kinase inhibitors for the treatment of RET-altered thyroid cancers: Current knowledge and future directions.
Hamidi S et al.
Annales D'endocrinologie, 2024
Does Genotype-Specific Phenotype in Patients with Multiple Endocrine Neoplasia Type 2 Occur as Current Guidelines Predict?
Binter T et al.
Cancers, 2024
Multiple endocrine neoplasia type 2: towards a risk-based approach integrating molecular and biomarker results.
Machens A et al.
Current Opinion in Oncology, 2024
Unveiling new chapters in medullary thyroid carcinoma therapy: advances in molecular genetics and targeted treatment strategies.
Huai JX et al.
Frontiers in Endocrinology, 2024
Identifying Lymph Node Metastasis-Related Factors in Breast Cancer Using Differential Modular and Mutational Structural Analysis.
Liu X et al.
Interdisciplinary Sciences, Computational Life Sciences, 2023
Personalized Medicine in Medullary Thyroid Carcinoma: A Broad Review of Emerging Treatments.
Martins RS et al.
Journal of Personalized Medicine, 2023
Integrated proteogenomic characterization of medullary thyroid carcinoma.
Shi X et al.
Cell Discovery, 2022
Sex differences in MEN 2A penetrance and expression according to parental inheritance.
Machens A et al.
European Journal of Endocrinology, 2022
Comprehensive Assessment of Indian Variations in the Druggable Kinome Landscape Highlights Distinct Insights at the Sequence, Structure and Pharmacogenomic Stratum.
Panda G et al.
Frontiers in Pharmacology, 2022
Current Guidelines for Management of Medullary Thyroid Carcinoma.
Kim M et al.
Endocrinology and Metabolism (seoul, Korea), 2021
The importance of the RET gene in thyroid cancer and therapeutic implications.
Salvatore D et al.
Nature Reviews. Endocrinology, 2021
Role of tissue and circulating microRNAs and DNA as biomarkers in medullary thyroid cancer.
Chiacchiarini M et al.
Pharmacology & Therapeutics, 2021
Diagnostic Challenges of Medullary Thyroid Carcinoma.
Leimbach RD et al.
Oncology, 2021
Genetic testing in endocrine surgery: Opportunities for precision surgery.
Alobuia W et al.
Surgery, 2020
Primary hyperparathyroidism as first manifestation in multiple endocrine neoplasia type 2A: an international multicenter study.
Larsen LV et al.
Endocrine Connections, 2020
Ret Receptor Has Distinct Alterations and Functions in Breast Cancer.
Gattelli A et al.
Journal of Mammary Gland Biology and Neoplasia, 2020
Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating RET Alterations and Oncogenic Signaling Pathway Aberrations.
Rich TA et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2019
Long-term outcome after DNA-based prophylactic neck surgery in children at risk of hereditary medullary thyroid cancer.
Machens A et al.
Best Practice & Research. Clinical Endocrinology & Metabolism, 2019
RET rearrangements are actionable alterations in breast cancer.
Paratala BS et al.
Nature Communications, 2018
Genotype-specific progression of hereditary medullary thyroid cancer.
Machens A et al.
Human Mutation, 2018
RET mutation heterogeneity in primary advanced medullary thyroid cancers and their metastases.
Romei C et al.
Oncotarget, 2018
Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers.
Roskoski R et al.
Pharmacological Research, 2018
Medullary Thyroid Carcinoma in MEN2A: ATA Moderate- or High-Risk RET Mutations Do Not Predict Disease Aggressiveness.
Voss RK et al.
The Journal of Clinical Endocrinology and Metabolism, 2017
Risk Profile of the RET A883F Germline Mutation: An International Collaborative Study.
Mathiesen JS et al.
The Journal of Clinical Endocrinology and Metabolism, 2017
Surgical approaches in hereditary endocrine tumors.
Iacobone M et al.
Updates in Surgery, 2017
Diversity of mutations in the RET proto-oncogene and its oncogenic mechanism in medullary thyroid cancer.
Hedayati M et al.
Critical Reviews in Clinical Laboratory Sciences, 2016
C-Cell Neoplasia in Asymptomatic Carriers of RET Mutation in Extracellular Cysteine-Rich and Intracellular Tyrosine Kinase Domain.
Abi-Raad R et al.
Human Pathology, 2015
Skewed mutational spectrum of RET proto-oncogene Exon10 in Iranian patients with medullary thyroid carcinoma.
Yeganeh MZ et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine, 2015
Twenty years of lesson learning: how does the RET genetic screening test impact the clinical management of medullary thyroid cancer?
Romei C et al.
Clinical Endocrinology, 2015
Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.
Wells SA et al.
Thyroid : Official Journal of the American Thyroid Association, 2015
In silico analysis of RET variants in medullary thyroid cancer: from the computer to the bedside.
Heineman TE et al.
Otolaryngology--head and Neck Surgery : Official Journal of American Academy of Otolaryngology-head and Neck Surgery, 2015
Comprehensive assessment of the disputed RET Y791F variant shows no association with medullary thyroid carcinoma susceptibility.
Toledo RA et al.
Endocrine-related Cancer, 2015
Tandem Germline RET Mutations in a Family Pathogenetic for Multiple Endocrine Neoplasia 2B, Confirmed by a Natural Experiment.
Kihara M et al.
European Thyroid Journal, 2014
The value of genetic screening in medullary thyroid cancer.
Pappa T et al.
Expert Review of Endocrinology & Metabolism, 2014
Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update.
Wells SA et al.
The Journal of Clinical Endocrinology and Metabolism, 2013
Differential gene expression of medullary thyroid carcinoma reveals specific markers associated with genetic conditions.
Maliszewska A et al.
The American Journal of Pathology, 2013
Consensus: a framework for evaluation of uncertain gene variants in laboratory test reporting.
Crockett DK et al.
Genome Medicine, 2012
Management of medullary thyroid carcinoma and MEN2 syndromes in childhood.
Waguespack SG et al.
Nature Reviews. Endocrinology, 2011
Variant identification in multi-sample pools by illumina genome analyzer sequencing.
Margraf RL et al.
Journal of Biomolecular Techniques : Jbt, 2011
RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC).
Romei C et al.
Clinical Endocrinology, 2011
Predominant RET Germline Mutations in Exons 10, 11, and 16 in Iranian Patients with Hereditary Medullary Thyroid Carcinoma.
Hedayati M et al.
Journal of Thyroid Research, 2011